Welcome to our dedicated page for RESMED SEC filings (Ticker: RSMDF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on RESMED's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into RESMED's regulatory disclosures and financial reporting.
A shareholder in RMD filed a Form 144 notice to sell 50 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of 13000.00, on or about 02/04/2026 on the NYSE. The 50 shares were acquired as restricted stock vesting on 11/11/2021 as compensation from the issuer. Over the past three months, the same account has sold 50 shares of common stock on 12/01/2025 for gross proceeds of 12208.00 and another 50 shares on 01/02/2026 for gross proceeds of 12087.50.
ResMed Inc.’s Chief Financial Officer Brett Sandercock reported a planned sale of company stock. On February 2, 2026, he sold 1,000 shares of ResMed common stock at $257.03 per share under a Rule 10b5-1 trading plan adopted on February 19, 2025.
After this transaction, Sandercock directly holds 85,495 ResMed shares. Rule 10b5-1 plans allow executives to pre-schedule trades, helping separate routine portfolio moves from day-to-day market or company news.
Brett Sandercock filed a notice of proposed sale of 1,000 shares of common stock with an aggregate market value of 257,030.00, to be sold through Fidelity Brokerage Services LLC on the NYSE around 02/02/2026.
The 1,000 shares were acquired on 11/11/2022 through restricted stock vesting from the issuer as compensation. Over the prior three months, Brett Sandercock sold 3,000 common shares on 11/03/2025 for gross proceeds of 742,620.00, 1,000 shares on 12/01/2025 for 244,160.00, and 1,000 shares on 01/02/2026 for 241,750.00.
ResMed Inc. filed a current report describing its latest quarterly results and a new dividend declaration. The company issued a press release covering operations for the quarter ended December 31, 2025, which is furnished as an exhibit and not treated as filed for liability purposes.
ResMed’s board declared a quarterly cash dividend of US $0.60 per share, with a record date of February 12, 2026, payable on March 19, 2026. The dividend will be paid in U.S. dollars to NYSE common stockholders. Holders of CHESS Depositary Instruments on the ASX will receive the equivalent in Australian dollars based on the exchange rate on the record date, reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date is February 11, 2026 for both common stock and CDIs, and ResMed obtained an ASX waiver to defer conversions between its common stock and CDI registers from February 11–12, 2026.
ResMed Inc. director Peter C. Farrell reported a sale of company stock. On January 7, 2026, he sold 2,000 shares of ResMed common stock at a price of $248.83 per share. After this transaction, he beneficially owned 66,773 shares directly. The filing notes that the trade was conducted under a Rule 10b5-1 trading plan that was adopted on August 12, 2025, which is a pre-arranged plan that allows insiders to systematically sell shares over time.
ResMed Inc.'s Chairman and CEO Michael J. Farrell reported an options exercise and stock sale. On January 7, 2026, he exercised 4,991 ResMed common stock options at an exercise price of $146.34 per share, receiving the same number of ResMed common shares. On the same day, he sold 4,991 ResMed common shares at a weighted average price of $248.4603 per share, in multiple trades between $246.801 and $249.969.
The transactions were conducted under a Rule 10b5-1 trading plan adopted on October 31, 2024. Following these transactions, Farrell directly beneficially owned 466,223 ResMed common shares, held in his own name, and indirectly beneficially owned 2,090 shares through the Lisette and Michael Farrell Family Trust. He also held 49,912 ResMed common stock options after the reported exercise; these options first became exercisable on November 11, 2020 and vest one-third per year.
RMD received a Rule 144 notice indicating that shareholder Peter C Farrell plans to sell 2,000 shares of common stock through Merrill Lynch on or about 01/07/2026 on the NYSE. The filing lists an aggregate market value of $497,580 for the planned sale and notes that 44,448,959 shares of the same class were outstanding.
The 2,000 shares to be sold were acquired on 11/11/2014 via a stock option from Peter C Farrell and paid for in cash. Over the past three months, Peter C Farrell previously sold 2,000 shares on 11/12/2025 for gross proceeds of $504,020 and another 2,000 shares on 12/04/2025 for $502,860. By signing the notice, the seller represents that he does not know of any material adverse information about the issuer’s operations that has not been publicly disclosed.
Michael Farrell filed a notice to sell 4,991 shares of RMD common stock through Fidelity Brokerage Services LLC on January 7, 2026, with an aggregate market value of $1,240,065.29 on the NYSE.
The shares were acquired the same day via a cash exercise of a stock option originally granted on November 21, 2019. RMD has 145,966,294 common shares outstanding, and over the prior three months Farrell sold 8,009, 8,011, and 4,991 common shares in separate transactions, generating gross proceeds of $2,265,332.03, $2,000,772.95, and $1,254,795.79, respectively.
ResMed Inc.'s Chief Financial Officer reported a small planned share sale. On 01/02/2026, the CFO sold 1,000 shares of ResMed common stock at a price of $241.75 per share in an open market transaction coded as a sale. The filing shows that after this transaction, the officer directly beneficially owns 86,495 shares of ResMed common stock.
The transaction was made under a Rule 10b5-1 trading plan that was adopted on February 19, 2025, indicating it was pre-arranged under SEC rules rather than a discretionary trade at the time of sale.
ResMed Inc.'s Global General Counsel and Secretary reported a small stock sale in a Form 4 filing. On 01/02/2026, the officer sold 50 shares of ResMed common stock at a price of $241.75 per share. After this transaction, the officer beneficially owned 9,741 shares, held directly.
The filing notes that this transaction was conducted under a pre-established Rule 10b5-1 trading plan that was adopted on February 28, 2025. Such plans allow insiders to sell shares according to predetermined instructions, helping separate routine portfolio management from the timing of any company news.